Roche Gives Up Daclizumab; PDL Seeking Asthma Partner

Hoffmann-La Roche Inc.'s decision to back out entirely of the deal with PDL BioPharma Inc. for Zenapax (daclizumab) leaves intact the biotech firm's main revenue sources - as well as a separate pact with Biogen Idec to develop the same antibody in multiple sclerosis - and Wall Street nipped PDL shares only slightly on the Roche news. (BioWorld Today)